Unicycive Therapeutics Inc
UNCY6.690USD
+0.500+8.08%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
139.49M시가총액
손실P/E TTM
자세한 내용은 Unicycive Therapeutics Inc 회사
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Inc 정보
종목 코드 UNCY
회사 이름Unicycive Therapeutics Inc
상장일Jun 17, 2021
CEOGupta (Shalabh)
직원 수22
유형Ordinary Share
회계 연도 종료Jun 17
주소4300 El Camino Real, Suite 210
도시LOS ALTOS
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94022
전화16503840642
웹사이트https://unicycive.com/
종목 코드 UNCY
상장일Jun 17, 2021
CEOGupta (Shalabh)
Unicycive Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, Feb 1
마지막 업데이트: Sun, Feb 1
주주
주주 유형
주주
주주
비율
Vivo Capital, LLC
8.33%
Millennium Management LLC
5.46%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
기타
73.49%
주주
주주
비율
Vivo Capital, LLC
8.33%
Millennium Management LLC
5.46%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
기타
73.49%
주주 유형
주주
비율
Hedge Fund
19.90%
Venture Capital
10.71%
Investment Advisor
4.05%
Individual Investor
2.93%
Investment Advisor/Hedge Fund
1.55%
Research Firm
0.29%
기타
60.57%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
65
6.67M
31.03%
-253.32K
2025Q3
61
5.54M
31.38%
-1.91M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Vivo Capital, LLC
1.79M
8.33%
+652.90K
+57.42%
Sep 30, 2025
Octagon Capital Advisors LP
1.00M
4.65%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
939.20K
4.37%
--
--
Sep 30, 2025
Great Point Partners, LLC
796.56K
3.71%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
658.88K
3.07%
+52.92K
+8.73%
Sep 30, 2025
Gupta (Shalabh K)
597.25K
2.78%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
2.2%
+1.00
+0.00%
Sep 30, 2025
Rosalind Advisors, Inc.
242.49K
1.13%
+242.49K
--
Apr 30, 2025
Geode Capital Management, L.L.C.
125.73K
0.58%
+66.94K
+113.87%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Jun 17, 2025
Merger
10→1
날짜
배당락일
유형
비율
Jun 17, 2025
Merger
10→1
